Current role for cytoreduction and HIPEC for gastric cancer with peritoneal disease
Hamza Khan, Fabian M. Johnston
Abstract
Gastric cancer (GC) is an aggressive malignancy with a high burden of peritoneal disease. Evidence regarding the use of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) to improve outcomes has been growing. However, given multiple limitations, there remains a lack of international consensus regarding the optimal treatment paradigm. This review article discusses the burden of peritoneal disease in GC patients and the role of CRS + HIPEC in all treatment intents-curative, prophylactic, and palliative.
Topics & Concepts
MedicineHyperthermic intraperitoneal chemotherapyCytoreductive surgeryDiseaseMalignancyCancerIntraperitoneal chemotherapyChemotherapyPeritoneal carcinomatosisCurative treatmentOncologyIntensive care medicineInternal medicineSurgeryGeneral surgeryOvarian cancerColorectal cancerIntraperitoneal and Appendiceal MalignanciesAppendicitis Diagnosis and ManagementOvarian cancer diagnosis and treatment